Serotonin 5-HT6 Receptor Antagonists in Alzheimer’s Disease: Therapeutic Rationale and Current Development Status

CNS Drugs

Volumn 31, Issue 1, 2017, Pages 19-32

  Ferrero, Hilda ^a   Solas, Maite ^a   Francis, Paul T ^b   Ramirez, Maria J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SEROTONIN 6 ANTAGONIST; SEROTONIN 6 RECEPTOR; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; COGNITION; COGNITIVE DEFECT; DRUG EFFECT; DRUG STRUCTURE; HUMAN; NEUROPHYSIOLOGY; PALLIATIVE THERAPY; PATENT; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; ANIMAL; CLINICAL TRIAL (TOPIC); METABOLISM;

ALZHEIMER DISEASE; ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 85001029968     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-016-0399-3     Document Type: Article

References (108)

1. Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362:329–44.
2. Perry EK, Johnson M, Kerwin JM, Piggott MA, Court JA, Shaw PJ, et al. Convergent cholinergic activities in aging and Alzheimer’s disease. Neurobiol Aging. 1992;13:393–400.
3. Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 1999;22:273–80.
4. IPA. Behavioral and psychological signs and symptoms in dementia (BPSSD): implications for research and treatment. Int Psychogeriatr. 1996;8:215–552.
5. Levy ML, Cummings JL, Kahn-Rose R. Neuropsychiatric symptoms and cholinergic therapy for Alzheimer’s disease. Gerontology. 1999;45:15–22.
6. Martinson IM, Muwaswes M, Gilliss CL, Doyle GC, Zimmerman S. The frequency and troublesomeness of symptoms associated with Alzheimer’s disease. J Community Health Nurs. 1995;12:47–57.
7. Parnetti L, Amici S, Lanari A, Gallai V. Pharmacological treatment of non-cognitive disturbances in dementia disorders. Mech Ageing Dev. 2001;122:2063–9.
8. Codony X, Vela JM, Ramírez MJ. 5-HT6 receptor and cognition. Curr Opin Pharmacol. 2011;11:94–100.
9. Meneses A, Pérez-García G, Ponce-Lopez T, Castillo C. 5-HT6 receptor memory and amnesia: behavioral pharmacology: learning and memory processes. Int Rev Neurobiol. 2011;96:27–47.
10. Ramírez MJ. 5-HT6 receptors and Alzheimer’s disease. Alzheimer’s Res Ther. 2013;5:15.
11. Wicke K, Haupt A, Bespalov A. Investigational drugs targeting 5-HT6 receptors for the treatment of Alzheimer’s disease. Expert Opin Investig Drugs. 2015;24:1515–28.
12. Monsma FJJ, Shen Y, Ward RP, Hamblin MW, Sibley DR. Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. Mol Pharmacol. 1993;43:320–7.
13. Ruat M, Traiffort E, Arrang JM, Tardivel-Lacombe J, Diaz J, Leurs R, et al. A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. Biochem Biophys Res Commun. 1993;193(1):268–76.
14. Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE, et al. Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor. J Neurochem. 1996;66:47–56.
15. Wacker D, Wang C, Katritch V, Han GW, Huang X-P, Vardy E, et al. Structural features for functional selectivity at serotonin receptors. Science. 2013;340:615–9.
16. Comley RA, Salinas C, Mizrahi R, Vitcu I, Ng A, Hallett W, et al. Biodistribution and radiation dosimetry of the serotonin 5-HT6 ligand [11C]GSK215083 determined from human whole-body PET. Mol Imaging Biol. 2012;14:517–21.
17. Gerard C, Martres M, Lefevre K, Verge D, Lanfumey L, Doucet E, et al. Immuno-localization of serotonin 5-HT 6 receptor-like material in the rat central nervous system. Brain Res. 1997;746(1–2):207–19.
18. Hamon M, Doucet E, Lefèvre K, Miquel MC, Lanfumey L, Insausti R, et al. Antibodies and antisense oligonucleotide for probing the distribution and putative functions of central 5-HT6 receptors. Neuropsychopharmacology. 1999;21(2 Suppl):68S–76S.
19. de Jong I, Helboe L. Distribution of serotonine receptor 5-HT6 mRNA in selected neuronal populations in rat brain: a double-labelling in situ hybridization study. Alzheimer’s Dement. 2014;10:P925–6.
20. Gérard C, El Mestikawy S, Lebrand C, Adrien J, Ruat M, Traiffort E, et al. Quantitative RT-PCR distribution of serotonin 5-HT6 receptor mRNA in the central nervous system of control or 5,7-dihydroxytryptamine-treated rats. Synapse. 1996;23:164–73.
21. Brouard JT, Schweimer JV, Houlton R, Burnham KE, Quérée P, Sharp T. Pharmacological evidence for 5-HT6 receptor modulation of 5-HT neuron firing in vivo. ACS Chem Neurosci. 2015;6:1241–7.
22. Marcos B, Gil-Bea FJ, Hirst WD, García-Alloza M, Ramírez MJ. Lack of localization of 5-HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5-HT6 receptor-mediated acetylcholine release. Eur J Neurosci. 2006;24:1299–306.
23. Dawson L, Nguyen HQ, Li P. The 5-HT6 receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology. 2001;25:662–8.
24. Tassone A, Madeo G, Schirinzi T, Vita D, Puglisi F, Ponterio G, et al. Activation of 5-HT6 receptors inhibits corticostriatal glutamatergic transmission. Neuropharmacology. 2011;61:632–7.
25. Woolley ML, Marsden CA, Fone KC. 5-ht6 receptors. Curr Drug Targets CNS Neurol Disord. 2004;3:59–79.
26. Riemer C, Borroni E, Levet-trafit B, Martin JR, Poli S, Porter RHP, et al. Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-Bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. J Med Chem. 2003;46:1273–6.
27. Helboe L, Egebjerg J, de Jong IEM. Distribution of serotonin receptor 5-HT6 mRNA in rat neuronal subpopulations: a double in situ hybridization study. Neuroscience. 2015;310:442–54.
28. Dupuis DS, la Cour CM, Chaput C, Verrièle L, Lavielle G, Millan MJ. Actions of novel agonists, antagonists and antipsychotic agents at recombinant rat 5-HT6 receptors: a comparative study of coupling to Gαs. Eur J Pharmacol. 2008;588:170–7.
29. 2+ signaling using an enabling chimeric G-protein. Eur J Pharmacol. 2003;472:33–8.
30. Yun H-M, Kim S, Kim H-J, Kostenis E, Kim JI, Seong JY, et al. The novel cellular mechanism of human 5-HT6 receptor through an interaction with Fyn. J Biol Chem. 2007;282:5496–505.
31. Yun H-M, Baik J-H, Kang I, Jin C, Rhim H. Physical interaction of Jab1 with Human serotonin 6 G-protein-coupled receptor and their possible roles in cell survival. J Biol Chem. 2010;285:10016–29.
32. Ivachtchenko AV, Ivanenkov YA, Tkachenko SE. 5-Hydroxytryptamine subtype 6 receptor modulators: a patent survey. Expert Opin Ther Pat. 2010;20:1171–96.
33. Hirst WD, Abrahamsen B, Blaney FE, Calver AR, Aloj L, Price GW, et al. Differences in the central nervous system distribution and pharmacology of the mouse 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol. 2003;64:1295–308.
34. Kumari M, Chandra S, Tiwari N, Subbarao N. 3D QSAR, pharmacophore and molecular docking studies of known inhibitors and designing of novel inhibitors for M18 aspartyl aminopeptidase of Plasmodium falciparum. BMC Struct Biol. 2016;16:12.
35. Sleight AJ, Boess FG, Bös M, Levet-Trafit B, Riemer C, Bourson A. Characterization of Ro 04-6790 and Ro 63-0563: potent and selective antagonists at human and rat 5-HT6 receptors. Br J Pharmacol. 1998;124:556–62.
36. López-Rodríguez ML, Benhamú B, de la Fuente T, Sanz A, Pardo L, Campillo M. A three-dimensional pharmacophore model for 5-hydroxytryptamine6 (5-HT6) receptor antagonists. J Med Chem. 2005;48:4216–9.
37. Rossé G, Schaffhauser H. 5-HT6 receptor antagonists as potential therapeutics for cognitive impairment. Curr Top Med Chem. 2010;10:207–21.
38. Witty D, Ahmed M, Chuang TT. Advances in the design of 5-HT6 receptor ligands with therapeutic potential. Prog Med Chem. 2009;48:163–224.
39. Benhamú B, Martín-Fontecha M, Vázquez-Villa H, Pardo L, López-Rodríguez ML. Serotonin 5-HT 6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer’s disease. J Med Chem. 2014;57:7160–81.
40. 6 receptor antagonists: design, synthesis & biological evaluation. Molecules. 2016;21:E1070 (pii).
41. Upton N, Chuang TT, Hunter AJ, Virley DJ. 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer’s disease. Neurotherapeutics. 2008;5:458–69.
42. Van Loevezijn A, Venhorst J, Iwema Bakker WI, De Korte CG, De Looff W, Verhoog S, et al. N′-(Arylsulfonyl)pyrazoline-1-carboxamidines as novel, neutral 5-hydroxytryptamine 6 receptor (5-HT6R) antagonists with unique structural features. J Med Chem. 2011;54:7030–54.
43. Yahiaoui S, Hamidouche K, Ballandonne C, Davis A, de Oliveira Santos JS, Freret T, et al. Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer’s disease. Eur J Med Chem. 2016;121:283–93.
44. Arnt J, Bang-Andersen B, Grayson B, Bymaster FP, Cohen MP, DeLapp NW, et al. Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010;13:1021–33.
45. Liu F, Majo VJ, Prabhakaran J, Milak MS, John Mann J, Parsey RV, et al. Synthesis and in vivo evaluation of [O-methyl-11C] N-[3,5-dichloro-2-(methoxy)phenyl]-4-(methoxy)-3-(1-piperazinyl)benzenesulfonamide as an imaging probe for 5-HT6 receptors. Bioorg Med Chem. 2011;19:5255–9.
46. Liu KG, Robichaud AJ. 5-HT6 medicinal chemistry. Int Rev Neurobiol. 2010;94:1–34.
47. Schmidt E, Kuwabara H, Areberg J, Zaidi E, Chamroonat W, Mathur A, et al. A clinical positron emission tomography (PET) study investigating occupancy at the 5-HT6 receptor after multiple oral doses of LU AE58054 to healthy men. Alzheimer’s Dement. 2014;10:P925.
48. Becker G, Colomb J, Sgambato-Faure V, Tremblay L, Billard T, Zimmer L. Preclinical evaluation of [18F]2FNQ1P as the first fluorinated serotonin 5-HT6 radioligand for PET imaging. Eur J Nucl Med Mol Imaging. 2015;42:495–502.
49. 6) receptors in vivo. Eur J Pharmacol. 2012;676:6–11.
50. Glennon RA, Lee M, Rangisetty JB, Dukat M, Roth BL, Savage JE, et al. 2-Substituted tryptamines: agents with selectivity for 5-HT(6) serotonin receptors. J Med Chem. 2000;43(5):1011–8.
51. Cole DC, Lennox WJ, Lombardi S, Ellingboe JW, Bernotas RC, Tawa GJ, et al. Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT 6 receptor agonists and antagonists. J Med Chem. 2005;48:353–6.
52. Mattsson C, Sonesson C, Sandahl A, Greiner HE, Gassen M, Plaschke J, et al. 2-Alkyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists. Bioorg Med Chem Lett. 2005;15:4230–4.
53. Cole DC, Stock JR, Lennox WJ, Bernotas RC, Ellingboe JW, Boikess S, et al. Discovery of N1-(6-Chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT 6 receptor agonist. J Med Chem. 2007;50:5535–8.
54. Russell MGN, Baker RJ, Barden L, Beer MS, Bristow L, Broughton HB, et al. N-Arylsulfonylindole derivatives as serotonin 5-HT(6) receptor ligands. J Med Chem. 2001;44(23):3881–95.
55. Jastrzêbska-Wiêsek M, Siwek A, Kazek G, Nawieśniak B, Partyka A, Marcinkowska M, et al. Partial agonist efficacy of EMD386088, a 5-HT6 receptor ligand, in functional in vitro assays. Pharmacol Rep. 2013;65(4):998–1005.
56. Pereira M, Martynhak BJ, Andreatini R, Svenningsson P. 5-HT6 receptor agonism facilitates emotional learning. Front Pharmacol. 2015;6:200.
57. de Foubert G, O’Neill MJ, Zetterström TSC. Acute onset by 5-HT6-receptor activation on rat brain brain-derived neurotrophic factor and activity-regulated cytoskeletal-associated protein mRNA expression. Neuroscience. 2007;147:778–85.
58. Yun H-M, Rhim H. 5-HT6 receptor ligands, EMD386088 and SB258585, differentially regulate 5-HT6 receptor-independent events. Toxicol In Vitro. 2011;25:2035–40.
59. Ivachtchenko AV, Ivanenkov YA. 5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivatives. Expert Opin Ther Pat. 2012;22:917–64.
60. Ivachtchenko AV, Ivanenkov YA, Skorenko AV. 5-HT(6) receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffolds. Expert Opin Ther Pat. 2012;22:1123–68.
61. Cavallaro S. Genomic analysis of serotonin receptors in learning and memory. Behav Brain Res. 2008;195:2–6.
62. Chen KH, Reese EA, Kim H-W, Rapoport SI, Rao JS. Disturbed neurotransmitter transporter expression in Alzheimer’s disease brain. J Alzheimer’s Dis. 2011;26:755–66.
63. Bourson A, Borroni E, Austin RH, Monsma FJ Jr, Sleight AJ. Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides. J Pharmacol Exp Ther. 1995;274:173–80.
64. Lindner MD, Hodges DB, Hogan JB, Orie AF, Corsa JA, Barten DM, et al. An assessment of the effects of serotonin 6 (5-HT6) receptor antagonists in rodent models of learning. J Pharmacol Exp Ther. 2003;307(2):682–91.
65. Russell M, Dias R. Memories are made of this (perhaps): a review of serotonin 5-HT6 receptor ligands and their biological functions. Curr Top Med Chem. 2002;2:643–54.
66. Marcos B, Cabero M, Solas M, Aisa B, Ramirez MJ. Signalling pathways associated with 5-HT6 receptors: relevance for cognitive effects. Int J Neuropsychopharmacol. 2010;13:775–84.
67. Huerta-Rivas A, Pérez-García G, González-Espinosa C, Meneses A. Time-course of 5-HT6 receptor mRNA expression during memory consolidation and amnesia. Neurobiol Learn Mem. 2010;93:99–110.
68. Mitchell ES, Sexton T, Neumaier JF. Increased expression of 5-HT6 receptors in the rat dorsomedial striatum impairs instrumental learning. Neuropsychopharmacology. 2007;32:1520–30.
69. de Bruin NMWJ, van Loevezijn A, Wicke KM, de Haan M, Venhorst J, Lange JHM, et al. The selective 5-HT6 receptor antagonist SLV has putative cognitive- and social interaction enhancing properties in rodent models of cognitive impairment. Neurobiol Learn Mem. 2016;133:100–17.
70. Peele DB, Vincent A. Strategies for assessing learning and memory, 1978–1987: a comparison of behavioral toxicology, psychopharmacology, and neurobiology. Neurosci Biobehav Rev. 1989;13:317–22.
71. Hirst WD, Stean TO, Rogers DC, Sunter D, Pugh P, Moss SF, et al. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol. 2006;553:109–19.
72. Foley AG, Murphy KJ, Hirst WD, Gallagher HC, Hagan JJ, Upton N, et al. The 5-HT(6) receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats. Neuropsychopharmacology. 2004;29:93–100.
73. Meneses A. Effects of the 5-HT(6) receptor antagonist Ro 04-6790 on learning consolidation. Behav Brain Res. 2001;118:107–10.
74. Meneses A. Role of 5-HT6 receptors in memory formation. Drug News Perspect. 2001;14:396–400.
75. Perez-García GS, Meneses A. Effects of the potential 5-HT7 receptor agonist AS 19 in an autoshaping learning task. Behav Brain Res. 2005;163:136–40.
76. Schreiber R, Vivian J, Hedley L, Szczepanski K, Secchi RL, Zuzow M, et al. Effects of the novel 5-HT(6) receptor antagonist RO4368554 in rat models for cognition and sensorimotor gating. Eur Neuropsychopharmacol. 2007;17:277–88.
77. Fone KCF. Selective 5-HT6 compounds as a novel approach to the treatment of Alzheimer disease. J Pharmacol Sci. 2006;101:53.
78. Mitchell ES, Neumaier JF. 5-HT6 receptors: a novel target for cognitive enhancement. Pharmacol Ther. 2005;108:320–33.
79. Meneses A. Serotonin, neural markers, and memory. Front Pharmacol. 2015;6:1–7.
80. Marcos B, Chuang TT, Gil-Bea FJ, Ramirez MJ. Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat. Br J Pharmacol. 2008;155:434–40.
81. Da Silva Costa-Aze V, Quiedeville A, Boulouard M, Dauphin F. 5-HT6 receptor blockade differentially affects scopolamine-induced deficits of working memory, recognition memory and aversive learning in mice. Psychopharmacology. 2012;222:99–115.
82. de Bruin NMWJ, Prickaerts J, van Loevezijn A, Venhorst J, de Groote L, Houba P, et al. Two novel 5-HT6 receptor antagonists ameliorate scopolamine-induced memory deficits in the object recognition and object location tasks in Wistar rats. Neurobiol Learn Mem. 2011;96:392–402.
83. King MV, Fone KCF, Shacham S, Fichman M, Melendez R, Orbach P, et al. Combination of sub-threshold doses of aricept and PRX-07034, a novel 5-HT6 receptor antagonist, enhances novel object discrimination (NOD) memory. J Pharmacol Sci. 2006;101:150.
84. Więckowska A, Kołaczkowski M, Bucki A, Godyń J, Marcinkowska M, Więckowski K, et al. Novel multi-target-directed ligands for Alzheimer’s disease: combining cholinesterase inhibitors and 5-HT6 receptor antagonists. Design, synthesis and biological evaluation. Eur J Med Chem. 2016;124:63–81.
85. King MV, Marsden CA, Fone KCF. A role for the 5-HT(1A), 5-HT4 and 5-HT6 receptors in learning and memory. Trends Pharmacol Sci. 2008;29:482–92.
86. Wilson C, Terry AV. Enhancing cognition in neurological disorders: potential usefulness of 5-HT6 antagonists. Drugs Future. 2009;34:969–75.
87. Fone KCF. An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function. Neuropharmacology. 2008;55:1015–22.
88. Kendall I, Slotten HA, Codony X, Burgueño J, Pauwels PJ, Vela JM, et al. E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. Psychopharmacology. 2011;213:413–30.
89. Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther. 2008;117:207–31.
90. Nikiforuk A. The procognitive effects of 5-HT6 receptor ligands in animal models of schizophrenia. Rev Neurosci. 2014;25:367–82.
91. Roberts JC, Reavill C, East SZ, Harrison PJ, Patel S, Routledge C, et al. The distribution of 5-HT(6) receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT(6) receptor antagonist [(125)I]SB-258585. Brain Res. 2002;934:49–57.
92. Zajdel P, Marciniec K, Satała G, Canale V, Kos T, Partyka A, et al. N1-azinylsulfonyl-1H-indoles: 5-HT6 receptor antagonists with procognitive and antidepressant-like properties. ACS Med Chem Lett. 2016;7:618–22.
93. Wesołowska A, Nikiforuk A. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression. Neuropharmacology. 2007;52:1274–83.
94. Hirano K, Piers TM, Searle KL, Miller ND, Rutter AR, Chapman PF. Procognitive 5-HT6 antagonists in the rat forced swimming test: potential therapeutic utility in mood disorders associated with Alzheimer’s disease. Life Sci. 2009;84:558–62.
95. Nikiforuk A, Kos T, Wesołowska A. The 5-HT6 receptor agonist EMD 386088 produces antidepressant and anxiolytic effects in rats after intrahippocampal administration. Psychopharmacology. 2011;217:411–8.
96. Carr GV, Schechter LE, Lucki I. Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists in rats. Psychopharmacology. 2011;213:499–507.
97. Svenningsson P, Tzavara ET, Qi H, Carruthers R, Witkin JM, Nomikos GG, et al. Biochemical and behavioral evidence for antidepressant-like effects of 5-HT6 receptor stimulation. J Neurosci. 2007;27:4201–9.
98. Jastrzębska-Więsek M, Siwek A, Partyka A, Kubacka M, Mogilski S, Wasik A, et al. Pharmacological evaluation of the anxiolytic-like effects of EMD 386088, a partial 5-HT6 receptor agonist, in the rat elevated plus-maze and Vogel conflict tests. Neuropharmacology. 2014;85:253–62.
99. Garcia-Alloza M, Hirst WD, Chen CPL-H, Lasheras B, Francis PT, Ramírez MJ. Differential involvement of 5-HT(1B/1D) and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer’s disease. Neuropsychopharmacology. 2004;29:410–6.
100. Foley AG, Hirst WD, Gallagher HC, Barry C, Hagan JJ, Upton N, et al. The selective 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats. Neuropharmacology. 2008;54:1166–74.
101. Routledge C, Bromidge SM, Moss SF, Price GW, Hirst W, Newman H, et al. Characterization of SB-271046: a potent, selective and orally active 5-HT(6) receptor antagonist. Br J Pharmacol. 2000;130:1606–12.
102. 2+, ERK1/2 and Fyn kinase through a full activation of cloned human 5-HT6 receptors. Eur J Pharmacol. 2011;661:8–14.
103. Mitchell ES. 5-HT6 receptor ligands as antidementia drugs. In: Borsini F, editor. International review of neurobiology. pharmacology of 5-HT6 receptors, Part II. Pomezia: Academic Press; 2011. p. 163–87.
104. Nirogi R, Kandikere V, Mudigonda K, Bhyrapuneni GJV. Safety, tolerability and pharmacokinetics of SUVN-502: a 5-HT6 receptor antagonist, first in human phase-1 single ascending dose (SAD) study. Alzheimers Dement. 2009;5:1–251.
105. Brisard C, Safirstein B, Booth K, Hua L, Brault Y, Raje S, et al. Safety, tolerability, and preliminary efficacy of SAM-531, a 5HT-6 antagonist, in subjects with mild-to-moderate Alzheimer’s disease: results from a phase 2a study. Alzheimers Dement. 2010;6:1–457.
106. Ivachtchenko AV, Lavrovsky Y, Okun I. AVN-101: a multi-target drug candidate for the treatment of CNS disorders. J Alzheimers Dis. 2016;53:583–620.
107. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer’s disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008;372:207–15.
108. Jones RW. Dimebon disappointment. Alzheimers Res Ther. 2010;2:25.